Bronchitol mannitol: Phase II started

Pharmaxis began the double-blind, placebo-controlled, crossover, international Phase II DPMCF204 trial to evaluate twice-daily 400 mg Bronchitol for 8 weeks in about 160 patients ages 6-17 years. Pharmaxis said the trial is a requirement of its European marketing approval for adults and may form part of an application to extend the approval to treat children and adolescents with CF. ...